Isotretinion use and risk of depression, psychotic symptoms, suicide, and attempted suicide

Susan S. Jick, Hilal D Maradit Kremers, Catherine Vasilakis-Scaramozza

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

Background: It has been suggested that there is a causal association between isotretinoin therapy and the risk of depression, psychotic symptoms, suicide, and attempted suicide. Objective: To further investigate the proposed association between isotretinoin therapy and the risk of depression, psychotic symptoms, suicide, and attempted suicide using a formal study design. Design: Large population-based cohort studies. Setting: The Canadian Saskatchewan Health Database and the United Kingdom General Practice Research Database. Patients: Data were analyzed for 7195 isotretinoin users and 13 700 oral antibiotic users with ache from the Canadian Saskatchewan Health Database and for 340 isotretinoin users and 676 oral antibiotic users with ache from the United Kingdom General Practice Research Database. All subjects had computer-recorded histories of between 6 months and 5 years before, and at least 12 months after, their first isotretinoin or antibiotic prescription. Outcome Measure: Prevalence rates of neurotic and psychotic disorders, suicide, and attempted suicide were compared between isotretinoin and antibiotic users and within isotretinoin users as their own comparison (pretreatment vs posttreatment). The results were expressed as relative risks, calculated using multiple logistic regression analyses. Results: Relative risk estimates, comparing isotretinoin use and oral antibiotic use with nonexposure to either drug for newly diagnosed depression or psychosis, were approximately 1.0 regardless of the data source. Similarly, relative risk estimates were all around 1.0 when comparing before with after isotretinoin use. The relative risk estimate for suicide and attempted suicide was 0.9 (95% confidence interval, 0.3-2.4) when comparing current isotretinoin exposure with nonexposure. Conclusions: This study provides no evidence that use of isotretinoin is associated with an increased risk for depression, suicide, or other psychiatric disorders.

Original languageEnglish (US)
Pages (from-to)1231-1236
Number of pages6
JournalArchives of Dermatology
Volume136
Issue number10
StatePublished - 2000
Externally publishedYes

Fingerprint

Isotretinoin
Attempted Suicide
Suicide
Depression
Anti-Bacterial Agents
Databases
Saskatchewan
General Practice
Psychotic Disorders
Pain
Neurotic Disorders
Information Storage and Retrieval
Health
Research
Prescriptions
Psychiatry
Cohort Studies
Logistic Models
Regression Analysis
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Dermatology

Cite this

Isotretinion use and risk of depression, psychotic symptoms, suicide, and attempted suicide. / Jick, Susan S.; Maradit Kremers, Hilal D; Vasilakis-Scaramozza, Catherine.

In: Archives of Dermatology, Vol. 136, No. 10, 2000, p. 1231-1236.

Research output: Contribution to journalArticle

Jick, Susan S. ; Maradit Kremers, Hilal D ; Vasilakis-Scaramozza, Catherine. / Isotretinion use and risk of depression, psychotic symptoms, suicide, and attempted suicide. In: Archives of Dermatology. 2000 ; Vol. 136, No. 10. pp. 1231-1236.
@article{4b354a14efee4d7fb2822d85b49d1744,
title = "Isotretinion use and risk of depression, psychotic symptoms, suicide, and attempted suicide",
abstract = "Background: It has been suggested that there is a causal association between isotretinoin therapy and the risk of depression, psychotic symptoms, suicide, and attempted suicide. Objective: To further investigate the proposed association between isotretinoin therapy and the risk of depression, psychotic symptoms, suicide, and attempted suicide using a formal study design. Design: Large population-based cohort studies. Setting: The Canadian Saskatchewan Health Database and the United Kingdom General Practice Research Database. Patients: Data were analyzed for 7195 isotretinoin users and 13 700 oral antibiotic users with ache from the Canadian Saskatchewan Health Database and for 340 isotretinoin users and 676 oral antibiotic users with ache from the United Kingdom General Practice Research Database. All subjects had computer-recorded histories of between 6 months and 5 years before, and at least 12 months after, their first isotretinoin or antibiotic prescription. Outcome Measure: Prevalence rates of neurotic and psychotic disorders, suicide, and attempted suicide were compared between isotretinoin and antibiotic users and within isotretinoin users as their own comparison (pretreatment vs posttreatment). The results were expressed as relative risks, calculated using multiple logistic regression analyses. Results: Relative risk estimates, comparing isotretinoin use and oral antibiotic use with nonexposure to either drug for newly diagnosed depression or psychosis, were approximately 1.0 regardless of the data source. Similarly, relative risk estimates were all around 1.0 when comparing before with after isotretinoin use. The relative risk estimate for suicide and attempted suicide was 0.9 (95{\%} confidence interval, 0.3-2.4) when comparing current isotretinoin exposure with nonexposure. Conclusions: This study provides no evidence that use of isotretinoin is associated with an increased risk for depression, suicide, or other psychiatric disorders.",
author = "Jick, {Susan S.} and {Maradit Kremers}, {Hilal D} and Catherine Vasilakis-Scaramozza",
year = "2000",
language = "English (US)",
volume = "136",
pages = "1231--1236",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Isotretinion use and risk of depression, psychotic symptoms, suicide, and attempted suicide

AU - Jick, Susan S.

AU - Maradit Kremers, Hilal D

AU - Vasilakis-Scaramozza, Catherine

PY - 2000

Y1 - 2000

N2 - Background: It has been suggested that there is a causal association between isotretinoin therapy and the risk of depression, psychotic symptoms, suicide, and attempted suicide. Objective: To further investigate the proposed association between isotretinoin therapy and the risk of depression, psychotic symptoms, suicide, and attempted suicide using a formal study design. Design: Large population-based cohort studies. Setting: The Canadian Saskatchewan Health Database and the United Kingdom General Practice Research Database. Patients: Data were analyzed for 7195 isotretinoin users and 13 700 oral antibiotic users with ache from the Canadian Saskatchewan Health Database and for 340 isotretinoin users and 676 oral antibiotic users with ache from the United Kingdom General Practice Research Database. All subjects had computer-recorded histories of between 6 months and 5 years before, and at least 12 months after, their first isotretinoin or antibiotic prescription. Outcome Measure: Prevalence rates of neurotic and psychotic disorders, suicide, and attempted suicide were compared between isotretinoin and antibiotic users and within isotretinoin users as their own comparison (pretreatment vs posttreatment). The results were expressed as relative risks, calculated using multiple logistic regression analyses. Results: Relative risk estimates, comparing isotretinoin use and oral antibiotic use with nonexposure to either drug for newly diagnosed depression or psychosis, were approximately 1.0 regardless of the data source. Similarly, relative risk estimates were all around 1.0 when comparing before with after isotretinoin use. The relative risk estimate for suicide and attempted suicide was 0.9 (95% confidence interval, 0.3-2.4) when comparing current isotretinoin exposure with nonexposure. Conclusions: This study provides no evidence that use of isotretinoin is associated with an increased risk for depression, suicide, or other psychiatric disorders.

AB - Background: It has been suggested that there is a causal association between isotretinoin therapy and the risk of depression, psychotic symptoms, suicide, and attempted suicide. Objective: To further investigate the proposed association between isotretinoin therapy and the risk of depression, psychotic symptoms, suicide, and attempted suicide using a formal study design. Design: Large population-based cohort studies. Setting: The Canadian Saskatchewan Health Database and the United Kingdom General Practice Research Database. Patients: Data were analyzed for 7195 isotretinoin users and 13 700 oral antibiotic users with ache from the Canadian Saskatchewan Health Database and for 340 isotretinoin users and 676 oral antibiotic users with ache from the United Kingdom General Practice Research Database. All subjects had computer-recorded histories of between 6 months and 5 years before, and at least 12 months after, their first isotretinoin or antibiotic prescription. Outcome Measure: Prevalence rates of neurotic and psychotic disorders, suicide, and attempted suicide were compared between isotretinoin and antibiotic users and within isotretinoin users as their own comparison (pretreatment vs posttreatment). The results were expressed as relative risks, calculated using multiple logistic regression analyses. Results: Relative risk estimates, comparing isotretinoin use and oral antibiotic use with nonexposure to either drug for newly diagnosed depression or psychosis, were approximately 1.0 regardless of the data source. Similarly, relative risk estimates were all around 1.0 when comparing before with after isotretinoin use. The relative risk estimate for suicide and attempted suicide was 0.9 (95% confidence interval, 0.3-2.4) when comparing current isotretinoin exposure with nonexposure. Conclusions: This study provides no evidence that use of isotretinoin is associated with an increased risk for depression, suicide, or other psychiatric disorders.

UR - http://www.scopus.com/inward/record.url?scp=0033623285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033623285&partnerID=8YFLogxK

M3 - Article

VL - 136

SP - 1231

EP - 1236

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 10

ER -